HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fludarabine combinations for patients with advanced marginal zone lymphomas--best treatment option or too toxic?

AuthorsStefan Peinert, Dennis Carney, H Miles Prince, E Henry Januszewicz, John F Seymour
JournalBritish journal of haematology (Br J Haematol) Vol. 146 Issue 6 Pg. 685-6 (Sep 2009) ISSN: 1365-2141 [Electronic] England
PMID19638019 (Publication Type: Comment, Letter)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab
  • Cyclophosphamide
  • Vidarabine
  • fludarabine
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia, Refractory (chemically induced)
  • Antibodies, Monoclonal (adverse effects)
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents (adverse effects)
  • Bone Marrow Diseases (chemically induced)
  • Cell Lineage (drug effects)
  • Cyclophosphamide (administration & dosage, adverse effects)
  • Disease-Free Survival
  • Drug Therapy, Combination
  • Humans
  • Lymphoma, B-Cell, Marginal Zone (drug therapy)
  • Middle Aged
  • Rituximab
  • Vidarabine (adverse effects, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: